Serabelisib is under clinical development by Petra Pharma and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Serabelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Serabelisib (TAK-117, INK1117) is under development for solid tumors, metastatic triple negative breast cancer, squamous Cell Carcinoma, transitional cell carcinoma, adenocarcinoma of colon and rectum, endometrial cancer, ovarian cancer, endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, mucinous adenocarcinoma, carcinosarcoma and endometrial carcinoma. It is administered through oral route in the form of capsule and tablet. It acts by targeting the PI3Kalpha isoform. It was under development for the treatment of advanced solid tumor malignancies including squamous non-small cell lung cancer, relapsed and refractory gastric cancer, metastatic clear cell renal cell carcinoma and adenocarcinoma of the gastroesophageal junction.
Petra Pharma overview
Petra Pharma, a subsidiary of Eli Lilly and Co, develops phosphoinositide (PI) signaling pathway inhibition for the treatment of cancer and other serious diseases. The company is headquartered in New York, the US.
For a complete picture of Serabelisib’s drug-specific PTSR and LoA scores, buy the report here.